HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Issue 1 (19th November 2014)
- Record Type:
- Journal Article
- Title:
- HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Issue 1 (19th November 2014)
- Main Title:
- HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer
- Authors:
- Chang, Hae Ryung
Nam, Seungyoon
Kook, Myeong-Cherl
Kim, Kyung-Tae
Liu, Xiuping
Yao, Hui
Jung, Hae Rim
Lemos, Robert
Seo, Hye Hyun
Park, Hee Seo
Gim, Youme
Hong, Dongwan
Huh, Iksoo
Kim, Young-Woo
Tan, Dongfeng
Liu, Chang-Gong
Powis, Garth
Park, Taesung
Liang, Han
Kim, Yon Hui - Abstract:
- Abstract : Background: Worldwide, gastric cancer (GC) is the fourth most common malignancy and the most common cancer in East Asia. Development of targeted therapies for this disease has focused on a few known oncogenes but has had limited effects. Objective: To determine oncogenic mechanisms and novel therapeutic targets specific for GC by identifying commonly dysregulated genes from the tumours of both Asian-Pacific and Caucasian patients. Methods: We generated transcriptomic profiles of 22 Caucasian GC tumours and their matched non-cancerous samples and performed an integrative analysis across different GC gene expression datasets. We examined the inhibition of commonly overexpressed oncogenes and their constituent signalling pathways by RNAi and/or pharmacological inhibition. Results: Hepatocyte nuclear factor-4α (HNF4α) upregulation was a key signalling event in gastric tumours from both Caucasian and Asian patients, and HNF4α antagonism was antineoplastic. Perturbation experiments in GC tumour cell lines and xenograft models further demonstrated that HNF4α is downregulated by AMPKα signalling and the AMPK agonist metformin; blockade of HNF4α activity resulted in cyclin downregulation, cell cycle arrest and tumour growth inhibition. HNF4α also regulated WNT signalling through its target gene WNT5A, a potential prognostic marker of diffuse type gastric tumours. Conclusions: Our results indicate that HNF4α is a targetable oncoprotein in GC, is regulated by AMPK signallingAbstract : Background: Worldwide, gastric cancer (GC) is the fourth most common malignancy and the most common cancer in East Asia. Development of targeted therapies for this disease has focused on a few known oncogenes but has had limited effects. Objective: To determine oncogenic mechanisms and novel therapeutic targets specific for GC by identifying commonly dysregulated genes from the tumours of both Asian-Pacific and Caucasian patients. Methods: We generated transcriptomic profiles of 22 Caucasian GC tumours and their matched non-cancerous samples and performed an integrative analysis across different GC gene expression datasets. We examined the inhibition of commonly overexpressed oncogenes and their constituent signalling pathways by RNAi and/or pharmacological inhibition. Results: Hepatocyte nuclear factor-4α (HNF4α) upregulation was a key signalling event in gastric tumours from both Caucasian and Asian patients, and HNF4α antagonism was antineoplastic. Perturbation experiments in GC tumour cell lines and xenograft models further demonstrated that HNF4α is downregulated by AMPKα signalling and the AMPK agonist metformin; blockade of HNF4α activity resulted in cyclin downregulation, cell cycle arrest and tumour growth inhibition. HNF4α also regulated WNT signalling through its target gene WNT5A, a potential prognostic marker of diffuse type gastric tumours. Conclusions: Our results indicate that HNF4α is a targetable oncoprotein in GC, is regulated by AMPK signalling through AMPKα and resides upstream of WNT signalling. HNF4α may regulate 'metabolic switch' characteristic of a general malignant phenotype and its target WNT5A has potential prognostic values. The AMPKα-HNF4α-WNT5A signalling cascade represents a potentially targetable pathway for drug development. … (more)
- Is Part Of:
- Gut. Volume 65:Issue 1(2016)
- Journal:
- Gut
- Issue:
- Volume 65:Issue 1(2016)
- Issue Display:
- Volume 65, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 65
- Issue:
- 1
- Issue Sort Value:
- 2016-0065-0001-0000
- Page Start:
- 19
- Page End:
- 32
- Publication Date:
- 2014-11-19
- Subjects:
- GASTRIC CANCER -- DRUG DEVELOPMENT -- ONCOGENES -- MOLECULAR BIOLOGY -- GENE EXPRESSION
Gastroenterology -- Periodicals
616.33 - Journal URLs:
- http://gut.bmjjournals.com ↗
http://www.bmj.com/archive ↗ - DOI:
- 10.1136/gutjnl-2014-307918 ↗
- Languages:
- English
- ISSNs:
- 0017-5749
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17852.xml